The European deadline for data collection and reporting of pharma spend is drawing ever closer.
From January 2016, healthcare companies will be duty bound to publicly disclose all transfers of value (TOV) made to healthcare professionals and organisations in accordance with the 2014 EFPIA Disclosure code.
While opinion may be divided as to the merits of this code, or even the end objective, it cannot be argued that its introduction has led pharma companies to re-evaluate their marketing strategies, event policies, systems and processes. In doing so, the EFPIA code, much the same as its US counterpart (Open Payments Act) has created a micro-industry within pharma, designed specifically to accommodate the code to ensure its compliance and greater transparency across the industry.
We highlighted ten steps to take to help meet these rules and achieve full TOV disclosure – focusing on event and meetings spend – to PMLiVE. You can see the full article here.